comprehensive -WSS

comprehensive

author：hotspot 2025-09-27 16:46:32 - browse：78

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： The unintended consequences of overturning Roe v. Wade

hotspot

WSS

Novo Nordisk touts Wegovy study, but still struggling with supply

Maui wildfire now ranks as the fifth

FDA panel to weigh safety of artificial wombs for preterm births

Surge in Apellis stock fueled by confidence in safety of its eye drug

FDA panel to weigh safety of artificial wombs for preterm births

FDA panel to weigh safety of artificial wombs for preterm births

knowledge

comprehensive

leisure time

Guidelines to prevent youth baseball injuries need more muscle

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wildfire smoke exposes gaps in outdoor worker protections

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Drug repurposing or repositioning? The language matters

White House Covid adviser calls on docs to combat misinformation

Hepatitis C has a cure — but many Americans still lack access to it

What happened to the House vote on health price transparency?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Schizophrenia gene found to be linked to cells' energy dysfunction

hotspot

Mark Cuban is blaming the wrong people for high drug costs

Free Covid tests will again be offered to all U.S. households

Senators push IRS to launch nonprofit hospital probe

Grad students accuse University of California of wage theft

Grad students accuse University of California of wage theft

Illinois Supreme Court finds assault weapons ban constitutional

entertainment

explore

hotspot

hotspot